Visceral Pain Model Development Service
Are you currently facing challenges in developing highly translatable pain models, or struggling to identify effective treatments for chronic visceral pain conditions? Our visceral pain models service helps you accelerate drug discovery and obtain highly predictive data through advanced preclinical models, comprehensive behavioral, and mechanistic readouts.
Visceral pain, arising from internal organs, represents a chronic and debilitating condition with a significant global burden. Preclinical visceral pain models are indispensable tools for dissecting its complex pathophysiology, from neuroanatomical pathways to molecular mechanisms including the crucial microbiome-gut-brain axis dysfunction. These models, spanning in vivo animal studies and advanced in vitro systems, are critical for accelerating the discovery and development of novel, effective analgesics for conditions like IBS, IBD, and endometriosis.
How Our Visceral Pain Models Can Assist Your Project?
Our Visceral Pain Models service delivers tailored solutions to unravel the complexities of visceral pain and identify promising therapeutic candidates. We provide precise, reliable, and translatable data, empowering you to make informed decisions in your drug development pipeline. Expect a collaborative partnership focused on addressing your specific research questions and accelerating your path to clinical success.
Discover How We Can Help - Request a Consultation
Workflow
Initiating a project with CBL for Visceral Pain Models involves a streamlined, collaborative process designed for maximum efficiency and scientific rigor. This systematic approach ensures that every stage, from initial concept to final data delivery, is meticulously executed to meet your research objectives.
- Required Starting Materials: To initiate your project, we typically require:
- Detailed information regarding your target or compound(s) of interest.
- Specific research questions and therapeutic goals.
- Relevant background literature or preliminary data.
- Final Deliverables: Upon project completion, you will receive:
- A Comprehensive Study Report (CSR) including all raw and analyzed data.
- Detailed Methodologies and Standard Operating Procedures (SOPs) used.
- Strategic Recommendations for future development.
- Estimated Timeframe: The typical timeframe for a visceral pain modeling project ranges from 8 to 16 weeks, depending on the complexity of the model, the number of compounds, and the specific endpoints required. Custom model development may extend this duration.
Why Choose Us?
Choosing CBL as your partner for visceral pain research means leveraging two decades of specialized expertise, state-of-the-art capabilities, and an unwavering commitment to scientific excellence. Our unique features and advantages are designed to maximize your chances of success in a challenging therapeutic area.
Experience the Advantage - Get a Quote Today
Customer Reviews:
"Superior Translational Data Using CBL's Visceral Pain Models in our research has significantly improved our ability to predict clinical efficacy. Their colorectal distension model provided the most relevant data compared to other CROs we've worked with, leading to more confident go/no-go decisions." October 2024, Mar* An*on
"Invaluable Microbiome Expertise CBL's expertise in integrating microbiome analysis into their stress-induced visceral pain models was a game-changer for our novel biologic. Their thorough sequencing and metabolite analysis clarified the therapeutic mechanism, a depth of insight we hadn't found elsewhere." November 2024, Josph F**r
"Exceptional Customization & Support When our project required a highly specific endometriosis-pain model, CBL developed and validated a custom solution that perfectly met our needs. Their team's responsiveness and scientific rigor throughout the entire process were outstanding, truly facilitating our target validation efforts." December 2024, Sarh K**g
Visceral Pain Models
Visceral pain, often diffuse and referred, is a pervasive and debilitating condition characterized by discomfort originating from the internal organs. Unlike somatic pain, it is frequently accompanied by autonomic symptoms such as nausea, sweating, and changes in heart rate, making its diagnosis and management particularly challenging. Millions worldwide suffer from chronic visceral pain conditions, including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), endometriosis, chronic pancreatitis, and interstitial cystitis, collectively imposing an immense socio-economic burden. Despite its widespread impact, current therapeutic options are often limited in efficacy, highlighting an urgent unmet medical need for more targeted and effective treatments. In this critical context, robust preclinical models serve as the foundational bedrock for understanding the intricate mechanisms underlying visceral pain and for rigorously testing the efficacy and safety of new therapeutic candidates.
- Inflammatory Models
- Mechanical Stimulation Models
- Chemical Irritation Models
- Stress-Induced/Functional Models
- Surgical Models
- Genetic Models
- Readout Parameters and Endpoints: To accurately quantify visceral pain and therapeutic efficacy, a variety of readout parameters are employed:
Assessment | Description |
Behavioral Assessments | These include detailed analysis of visceromotor responses (VMR), abdominal guarding, grimace scales, and specific behaviors like writhing (abdominal constriction, trunk twisting, hind leg extension) observed in chemical irritation models. Pain threshold decrease to colonic distension is a critical quantitative measure in CRD and similar distension models. |
Electrophysiology | Techniques such as single-fiber recordings from visceral afferents provide direct evidence of neuronal excitability. |
Histopathology and Immunohistochemistry | These are used to assess inflammation, tissue damage, and changes in nerve density or expression of pain-related markers. |
Molecular Analysis | This involves quantifying gene expression and protein levels of various pain mediators and receptors using techniques like qPCR, Western blot, and ELISA. |
Biochemical Markers | Measurement of inflammatory cytokines and other mediators in tissue or serum provides insights into the underlying inflammatory processes. |
Microbiome Analysis | Advanced techniques like 16S rRNA gene sequencing and metabolomics are employed to characterize microbial communities and their metabolic products, offering insights into gut-brain axis modulation. |
What we can offer?
At CBL, our Visceral Pain Models service is meticulously designed to provide you with a distinctive advantage in your drug discovery journey. We don't just offer models; we provide a partnership rooted in scientific excellence and tailored solutions to meet your unique research demands.
- Comprehensive Model Portfolio: Access to a wide array of validated in vivo and in vitro visceral pain models, including inflammatory (e.g., TNBS-induced colitis), mechanical (e.g., colorectal distension), chemical, stress-induced, and functional models. This comprehensive offering ensures we have the right model for your specific research question.
- Customized Study Design & Optimization: We provide bespoke study design services, meticulously optimizing model parameters and experimental protocols to ensure maximum translational relevance and sensitivity to your unique compounds or targets. This includes developing novel models when required.
- Integrated Mechanistic Insights: Our capabilities extend beyond behavioral readouts to include advanced molecular, biochemical, electrophysiological, and crucially, microbiome analyses. This allows for a deeper understanding of underlying pain mechanisms and drug action.
- Scalable Solutions: Whether you require focused pilot studies or large-scale screening campaigns for multiple compounds, CBL possesses the capacity and expertise to efficiently execute projects of varying scopes, ensuring your project progresses seamlessly.
- Rigorous Quality Assurance: Our well-established quality system incorporates robust validation, aseptic procedures, and adherence to ethical guidelines. We ensure the stability and reproducibility of model performance, guaranteeing reliable and consistent data.
- Expert Data Interpretation & Strategic Guidance: Beyond providing raw data, our team of seasoned pain pharmacology specialists offers in-depth data analysis and interpretation, delivering actionable insights and strategic recommendations to guide your preclinical and clinical development decisions.
Related Services
Beyond our core visceral pain models, CBL offers a suite of complementary services designed to support your broader drug discovery and development efforts in pain and gastrointestinal research:
- Acute Pain Models
- Inflammatory Pain Models
- Biomarker Development & Validation
- Neuroinflammation Studies
Ready to advance your visceral pain research? Our expert scientific team is eager to discuss your specific project needs and demonstrate how CBL's unparalleled capabilities can accelerate your path to discovery.
Contact Our Team for More Information and to Discuss Your Project.
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody (NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Anti-CD20 Antibody (NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- iNeuMab™ Anti-GD2 Antibody (NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Human Dental Pulp Stem Cells (Cat#: NRZP-1122-ZP113)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)